Similarly, data from the Swedish registry show patients with RA (n = 69 308) treated with TNF inhibitors (adalimumab, certolizumab, etanercept, golimumab, and infliximab) or other biologic and targeted synthetic DMARDs (ABA, RTX, BARI, TOFA, and tocilizumab) within 2001–2018 had not increase cancer risk when compared to RA patients not treated with biologic and targeted synthetic DMARDs. This evidence concerns the gene TNF and rheumatoid arthritis.